D. E. Shaw & Co., Inc. Immuno Gen, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $30.8 Million - $74 Million	-2,472,442 Reduced 35.34%	4,522,797 $134 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $10.1 Million - $14.2 Million	714,723 Added 11.38%	6,995,239 $111 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $23.6 Million - $126 Million	6,280,516 New	6,280,516 $119 Million
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $881,580 - $1.22 Million	-193,754 Reduced 28.53%	485,378 $2.41 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $1.33 Million - $1.93 Million	-297,795 Reduced 30.48%	679,132 $3.25 Million

Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $865,462 - $1.58 Million	-274,750 Reduced 21.95%	976,927 $4.4 Million
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $2.58 Million - $4.53 Million	-606,029 Reduced 32.62%	1,251,677 $5.96 Million
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $1.09 Million - $1.71 Million	-228,529 Reduced 10.95%	1,857,706 $13.8 Million
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $439,485 - $576,934	-87,547 Reduced 4.03%	2,086,235 $11.8 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $1.98 Million - $2.95 Million	342,538 Added 18.71%	2,173,782 $14.3 Million
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $3.74 Million - $6.06 Million	575,562 Added 45.84%	1,831,244 $14.8 Million
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $1.43 Million - $2.95 Million	-385,734 Reduced 23.5%	1,255,682 $8.1 Million
Q3 2020 Nov 16, 2020	SELL	$3.45 - $4.89 $3.18 Million - $4.5 Million	-921,240 Reduced 35.95%	1,641,416 $5.91 Million
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $731,747 - $1.18 Million	220,406 Added 9.41%	2,562,656 $11.8 Million
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $448,719 - $1.44 Million	-211,660 Reduced 8.29%	2,342,250 $7.99 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $2.84 Million - $7.33 Million	1,263,448 Added 97.91%	2,553,910 $13 Million
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $1.77 Million - $2.7 Million	796,101 Added 161.04%	1,290,462 $3.12 Million
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $18,939 - $34,722	10,522 Added 2.17%	494,361 $1.07 Million
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $1.17 Million - $2.86 Million	483,839 New	483,839 $1.31 Million
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $98,925 - $129,523	-11,503 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $979,893 - $1.25 Million	-102,930 Reduced 89.95%	11,503 $112,000
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $766,701 - $1.48 Million	114,433 New	114,433 $1.2 Million
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $1.49 Million - $2.33 Million	-293,748 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $1.59 Million - $2.49 Million	293,748	293,748 $2.25 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account